Cediranib targeting of circulating VEGFR-1+ monocyte subpopulations
Hua Wu(Central Hospital of Wuhan), John V. Heymach(The University of Texas MD Anderson Cancer Center), Joachim Drevs(AstraZeneca (United Kingdom)), Ute Zirrgiebel(Johannes Gutenberg University Mainz), Kathryn S. McKee, Amado J. Zurita(The University of Texas MD Anderson Cancer Center), J. M. Jürgensmeier, Jane Robertson(Cancer Research UK), T. A. Puchalski(AstraZeneca (United States))
Cited by 1
Related Papers
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
|Journal of Clinical Oncology|2019|1.3k
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
|The Lancet Oncology|2016|1.1k
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
|Cancer Cell|2021|930
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
|New England Journal of Medicine|2020|879
A pan-cancer proteomic perspective on The Cancer Genome Atlas
|Nature Communications|2014|641